期刊
CLINICAL PHARMACOLOGY & THERAPEUTICS
卷 91, 期 1, 页码 134-142出版社
NATURE PUBLISHING GROUP
DOI: 10.1038/clpt.2011.266
关键词
-
资金
- AAAAI
- Am Col Osteopathic Physicians
- Asan Medical Center
- ATS
- AstraZeneca
- California Soc Allergy
- Convergent Health Solutions for Reviews and Trends in COPD
- COPD Foundation
- Creative Educational Concepts
- Dey
- Duke
- France Foundation
- Information TV
- University of California-Los Angeles
- Network for Continuing Education
- Novartis
- Nycomed
- Otsuka
- Pfizer
- Sarasota Memorial Hospital
- Spanish Thoracic Society
- University of Washington
- University of Alabama-Birmingham
- University of Pittsburgh
- University of British Columbia
- University of California-Davis
- VA Sioux Falls
- Biomarck
- Centocor
- GlaxoSmithKline
- Mpex
- Nabi
Phosphodiesterases (PDEs) are important modulators of inflammation and wound healing. In this capacity, specific targeting of PDEs for the treatment of many diseases, including chronic obstructive pulmonary disease (COPD), has been investigated. Currently, treatment of COPD is suboptimal. PDE4 modulates the inflammatory response of the lung, and inhibition of PDE4 may be a novel, COPD-specific approach toward more effective treatment strategies. This review describes the state of PDE4-inhibitor therapy for use in COPD treatment.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据